Skip to main content

Table 2 Summary of DVH analysis for PTV

From: Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients

  

Objective

Group A

Group B

Group C

PTV high dose

Volume [cm3]

 

142 ± 119

93 ± 68

144 ± 54

 

Mean [%]

100%

100.2 ± 0.8

100.5 ± 1.0

100.0 ± 0.2

 

D2% [%]

< 107%

104.1 ± 2.0

104.0 ± 2.2

104.4 ± 1.7

 

D5-95% [%]

Minimise

7.2 ± 2.0

7.0 ± 3.4

7.7 ± 2.7

 

D98% [%]

> 95%

94.6 ± 1.5

91.9 ± 6.5

93.6 ± 2.2

 

V95% [%]

100

97.2 ± 2.0

98.9 ± 1.7

96.5 ± 2.4

 

V107% [%]

0

0.7 ± 3.2

0.1 ± 0.2

0.4 ± 0.6

 

CI95%

1

1.21 ± 0.15

1.48 ± 0.43

1.06 ± 0.06

CTV high dose

Volume [cm3]

 

82 ± 43

59 ± 46

103 ± 41

 

Mean [%]

100%

100.9 ± 0.6

101.2 ± 1.3

100.6 ± 0.4

 

D2% [%]

< 107%

104.0 ± 1.2

104.0 ± 2.1

104.4 ± 1.8

 

D5-95% [%]

Minimise

4.6 ± 1.6

4.1 ± 1.8

5.6 ± 2.1

 

D98% [%]

> 95%

97.8 ± 1.1

98.3 ± 1.6

96.6 ± 2.0

 

V95% [%]

100

99.7 ± 0.7

99.6 ± 0.4

99.2 ± 1.1

 

V107% [%]

0

0.2 ± 0.5

0.1 ± 0.1

0.4 ± 0.6

PTV low dose

Volume [cm3]

 

253 ± 139

384 ± 282

 
 

D98% [%]

> 95%

95.1 ± 2.4

94.2 ± 2.6

 
 

V95% [%]

100

97.1 ± 5.0

97.8 ± 1.1

 
 

CI95%

1

1.38 ± 0.16

1.55 ± 0.20

 

CTV low dose

Volume [cm3]

 

184 ± 105

264 ± 178

 
 

D98% [%]

> 95%

100.7 ± 2.8

99.8 ± 2.1

 
 

V95% [%]

100

99.0 ± 4.0

99.7 ± 0.3

Â